Ongoing trials
| Clinical Study | Principal Investigator |
|---|---|
|
Protocol No: BIO-PERTUZ-301_HAB98922
A Multicenter, Double-Blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2(HER2)‑positive Early Stage or Locally Advanced Breast Cancer. |
Dr. Praveena Voonna |
|
Protocol No. LRP/LUBT022/2024/002
Study Title: “A randomized, double-blind, multi-center, active-control, parallel group study to compare efficacy, safety, immunogenicity and pharmacokinetics of Lupin’s Nivolumab (LUBT022) with Innovator’s Nivolumab in patients with locally advanced or metastatic non-small cell lung cancer”
|
Dr. Murali Krishna Voonna
|
|
Protocol No: J2J-MC-JZLH
Study Title: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence. |
Dr. Rajani Priya Yedla |
|
Protocol No: J3M-MC-JZQB
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with high PD-L1 expression (TPS ≥ 50%) (SUNRAY-01) The favorable safety profile of olomorasib makes it well suited to combination investigations. A phase 3 study investigating olomorasib plus pembrolizumab in first-line NSCLC is now enrolling (SUNRAY-01, NCT06119581) |
Dr. Rajani Priya Yedla |
